Johns Hopkins Remote Second Opinion, Reviewed

What a Johns Hopkins remote second opinion actually is

For many patients this is a pathology consultation rather than a whole-plan review. You or your physician submit your slides, tissue blocks, and pathology reports, a subspecialty pathologist re-reads the material, and you receive a written diagnostic opinion 1Ref 1Johns Hopkins Pathology (2025).Get a Second Opinion — Johns Hopkins Pathology.That Johns Hopkins Pathology offers a formal second-opinion consultation service in which patients or providers can submit pathology slides and reports for expert subspecialty re-review.. It is remote in the sense that the specimens and records travel rather than you, and the reviewer works from what is sent.

That scope is a strength and a limit. A slide re-read answers whether the tissue diagnosis is right, which is the foundation everything else is built on, but it is not automatically a review of your entire treatment plan. Eligibility, how you submit materials, and cost change over time, so the current process is worth confirming on the program's own page rather than from any summary.

A written diagnostic opinion typically states whether the reviewer confirms the original diagnosis, refines it, or disagrees, and it may note where the specimen is limited or where more tissue would help. That distinction — confirm, refine, or revise — is the practical output you are paying for, and it is what your own team reads alongside the original report.

What the center's own numbers show

Hopkins produced one of the field's landmark studies on exactly this. In a review of 6,171 second-opinion surgical pathology cases, 86 (1.4%) had a changed diagnosis of major clinical importance 2Ref 2Kronz JD, Westra WH, Epstein JI (1999).Mandatory second opinion surgical pathology at a large referral hospital.That a Johns Hopkins review of 6,171 second-opinion surgical pathology cases found 86 (1.4%) had a changed diagnosis of major clinical importance, altering therapy or prognosis., meaning the re-read altered therapy or prognosis. That figure is low, and it should be read honestly: the large majority of outside diagnoses were confirmed.

But the 1.4% is the whole point. When a diagnosis determines whether someone has surgery, chemotherapy, or neither, a small rate of major, care-changing corrections is exactly the argument for re-reading a high-stakes slide. The value is not that most reviews overturn the diagnosis; it is that the ones that do would otherwise have sent a patient down the wrong path.

Where a slide re-read changes the most

Discordance is not spread evenly; it concentrates in rare, ambiguous, and subspecialized tumors. When head-and-neck oncology specimens were routinely re-reviewed at one center, 22% were discordant with the outside read 3Ref 3Zhu GA, Lira R, Colevas AD (2016).Discordance in routine second opinion pathology review of head and neck oncology specimens: A single-center five year retrospective review.That among 667 head and neck oncology specimens routinely re-reviewed at a single center, 22% were discordant with the outside pathology assessment, showing higher discordance in this subspecialty.. For soft-tissue sarcomas, one series found outside labs agreed with the expert center only 28.3% of the time at private clinics, rising to 70.5% at the specialist center, and expert review corrected or confirmed the primary diagnosis in roughly three-quarters of cases 4Ref 4Lehnhardt M, Daigeler A, Hauser J, Puls A, Soimaru C, Kuhnen C, Steinau HU (2008).The value of expert second opinion in diagnosis of soft tissue sarcomas.That among 603 soft-tissue sarcoma patients, initial diagnostic concordance ranged from 28.3% at private clinics to 70.5% at the expert center, and expert second opinion improved or confirmed the correct primary diagnosis in 73.1%..

The rarer or more ambiguous the tumor, the more a subspecialty re-read can change. That is why matching the re-read to the specific diagnosis matters: a common, well-characterized cancer is less likely to be revised than an unusual sarcoma or an equivocal specimen, where a pathologist who sees hundreds of such cases a year adds the most.

It is not only slides — scans get re-read too

Some cases hinge on imaging rather than tissue, and imaging carries its own discordance. When subspecialists re-read outside PET-CT scans, they reached a different opinion about cancer in 13% of exams, and where the truth was later known the expert read was correct in about 89% 5Ref 5Ulaner GA, Mannelli L, Dunphy M (2017).Value of second-opinion review of outside institution PET-CT examinations.That subspecialist re-review of 240 outside PET-CT exams produced a discordant opinion of malignancy in 13%, and where a definitive diagnosis was later available the subspecialist read was correct in 89%.. A pathology-focused review answers the tissue question; it does not automatically re-read a scan.

So it is worth being clear with yourself about where your uncertainty sits. If the open question is what the biopsy shows, a slide re-read is the right tool. If it is what a scan means, an imaging re-read is a separate service. Some programs do both; a pathology consultation, on its own, is built for the slide.

How the remote review runs, and what you supply

The workflow is records and specimen logistics. You gather your pathology slides and tissue blocks, imaging on a disc or through a portal, and the associated reports, then submit them as the program directs. You have a right to these materials: federal rules bar information blocking and require access to your health information at no cost and without special effort 6Ref 6Office of the National Coordinator for Health Information Technology (ONC) (2020).ONC's Cures Act Final Rule.That the 21st Century Cures Act Final Rule prohibits information blocking and requires patients be able to access their electronic health information at no cost and without special effort, so records and slides can be obtained for a review., and pathology slides and blocks can be released for review.

Once a complete submission arrives, the subspecialist reviews it and returns a written opinion, typically within days to a couple of weeks depending on complexity. You then share that report with your treating team, who continue to coordinate your care. The opinion informs the plan; it does not, by itself, change your physician or your treatment.

Two practical points smooth the process. Sending the tissue blocks, not only the glass slides, lets the reviewer cut fresh sections and order additional stains if the case calls for it, which a slide alone cannot support. And tracking the shipment matters, because the blocks are often irreplaceable; most labs release them on loan and expect them returned. Keeping your treating team looped in throughout means the returned opinion reaches people who already have your full context.

How it compares to a whole-plan program

A pathology re-read and a full remote program answer different questions. The re-read asks whether the diagnosis is right; a whole-plan program asks whether the treatment is right. If your diagnosis is confirmed but the plan is complex, a broader review or a cancer center focused on your disease may add more than a slide re-read alone.

The same questions of subspecialty depth, cost, and turnaround apply across the field, whether you are weighing a johns hopkins second opinion, a mayo clinic remote second opinion, an md anderson second opinion, a mass general brigham second opinion, or a dana-farber online second opinion. If you want these remote second opinion programs compared side by side, that comparison lives elsewhere in this library; the right choice is the one whose specialists go deepest in your specific question.